A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was: in patients with concomitant aortic and mitral valve disease is aortic valve replacement with mitral valve plasty (MVP) superior to double valve replacement (DVR) in terms of improved long-term survival? Altogether 156 papers were found using the reported search, of which seven represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Out of seven papers, that simultaneously compare these two treatment modalities, three favor MVP combined with aortic valve replacement (AVR) over DVR, two papers advocate the opposite and two failed to find any significant difference in long-term survival, freedom from reoperation and thromboembolic and bleeding complications between these two surgical options. All data presented derive from level 2b evidence. Critical appraisal of these studies is constricted by the large heterogeneity of the patients, diversity in treatment protocols and inherent selection bias. We conclude that currently the available evidence is insufficient to prove that AVR with MVP is superior to DVR in patients with double valve disease.
Introduction
A best evidence topic was constructed according to a structured protocol. This is fully described in ICVTS w1x.
Three-part question
In patients with wconcomitant aortic and mitral valve diseasex is waortic valve replacement with mitral valve repairx superior to wdouble valve replacementx in terms of improved wlong-term survivalx?
Clinical scenario
You are seeing a 64-year-old female who has been referred for surgery with rheumatic heart disease. Echocardiography (ECHO) shows severe aortic stenosis and severe mitral regurgitation. In your department, it is a standard of care to perform double valve replacement (DVR) in patients with concomitant aortic and mitral valve disease. You are wondering if aortic valve replacement (AVR) combined with mitral valve plasty (MVP) would lead to improved long-term *Corresponding author. Tel.: q420 733 677 694; fax: q420 236 052 776. E-mail address: maub@ikem.cz (M. Urban).
survival when compared to DVR. You decide to perform a literature search to answer this question.
Search strategy
Medline search 1950 to July week 4 2010 using OVID interface w(exp aortic valveyAND replacement.mp.) or aortic valve replacement.mp. or aortic valve prosthesis.mp.x AND w(exp mitral valveyAND replacement.mp.) or mitral valve replacement.mp. or mitral valve prosthesis.mp. OR mitral replacement.mp.x AND (mitral repair or mitral valve repair.mp.).
Search outcome
One hundred and fifty-six papers were found using the reported search. From these seven papers were identified that provided the best evidence. These are presented in Table 1 .
Results
For patients with concomitant aortic and mitral valve disease, the overwhelming majority of aortic valves are replaced. While the replacement of the aortic valve at the time of double valve surgery is not contentious, the choice of mitral valve procedure (repair vs. replacement) remains (ns43) . They included patients with both rheumatic and non-rheumatic mitral disease. All prosthetic valves were mechanical. There were no significant differences in valve related deaths, anticoagulation related complications, or prosthetic valve endocarditis between the groups. They concluded that survival in patients with double valve disease is not significantly influenced by MVP. A study from the Northern New England Cardiovascular Disease Study Group w7x showed that in patients -70 years, either mechanical valves in both positions or a tissue atrioventricular (AV) and mitral repair had the lowest in-hospital mortality and the best long-term survival. In patients G70 years, tissue valves in both positions had the best inhospital and long-term survival.
Clinical bottom line
AVR with either MVP or MVR are two independent therapeutic techniques for treating patients with concomitant aortic and mitral valve disease. Evaluation and appraisal of the data presented is difficult due to heterogeneity in patients demographic profiles, etiology of mitral valve disease, different types of valves used for replacement, different duration of follow-up and differences in reporting valve and anticoagulation related adverse outcomes. The durability of MVP in combination with AVR depends on the underlying mitral valve pathology, technique of repair and individual surgeon's skill and experience. We conclude that Best Evidence Topic Downloaded from https://academic.oup.com/icvts/article-abstract/12/2/238/742525 by guest on 06 January 2019 whereas there are some data suggesting possible advantages of MVP over MVR in patients with double valve disease, currently the evidence is insufficient to advocate this treatment option as superior to DVR.
